Summary
Johnson & Johnson reported strong top-line growth for the second quarter and the first six months of 2005, with worldwide sales increasing by 11.1% year-over-year to $12.8 billion for the quarter and $25.6 billion for the six-month period. This growth was driven by robust performance across all business segments, particularly in the Medical Devices and Diagnostics segment which saw a 19.7% increase in quarterly sales, largely due to the success of the CYPHER(r) Sirolimus-eluting Stent. The Pharmaceutical segment also showed resilience, with notable growth in key products like RISPERDAL(r), REMICADE(r), and TOPAMAX(r), although PROCRIT(r)/EPREX(r) experienced a decline due to competition. Net earnings for the second quarter were $2.7 billion, a 9.1% increase compared to $2.5 billion in the prior year. Diluted earnings per share rose to $0.89 from $0.82. The company also demonstrated a commitment to shareholder returns by increasing its quarterly dividend by 15.8% and continuing its share repurchase program. While the company faces ongoing legal proceedings and patent challenges, particularly in the pharmaceutical and medical device sectors, management believes these matters, net of accrued liabilities, will not have a material adverse effect on the company's financial position, though they could impact quarterly results.
Key Highlights
- 1Worldwide sales increased by 11.1% year-over-year for both the second quarter ($12.8 billion) and the first six months ($25.6 billion) of 2005.
- 2The Medical Devices and Diagnostics segment showed significant growth, with quarterly sales up 19.7%, driven by the CYPHER(r) Sirolimus-eluting Stent.
- 3Pharmaceutical segment sales grew 3.7% in the quarter, boosted by strong performance in RISPERDAL(r), REMICADE(r), and TOPAMAX(r), while PROCRIT(r)/EPREX(r) faced competitive pressures.
- 4Net earnings for the second quarter reached $2.7 billion, an increase of 9.1% over the prior year, with diluted EPS growing to $0.89.
- 5The company declared a 15.8% increase in its quarterly cash dividend, reflecting confidence in its financial health and commitment to shareholder returns.
- 6Significant investment in Research & Development, with a 25.8% increase in R&D spending for the second quarter, signaling a focus on future innovation.
- 7The company is actively managing a portfolio of acquisitions, including recent ones like TransForm Pharmaceuticals, CLOSURE Medical, and Peninsula Pharmaceuticals, while continuing its defense in numerous legal proceedings and patent disputes.